Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AZ's XigDuo gets European nod, but it's the US that counts

This article was originally published in Scrip

Executive Summary

Combination diabetes drug XigDuo (dapagliflozin and metformin), developed as part of AstraZeneca and Bristol-Myers Squibb's now defunct joint venture (scripintelligence.com, 19 December 2013), has received final approval in Europe. But the win means little unless AstraZeneca, now marketing the drug alone, can beat rival Johnson & Johnson to have the first fixed-dose combination approval in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

SC024186

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel